{"id":390447,"date":"2019-04-12T00:00:00","date_gmt":"2019-04-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0012-2018-biopharma-chronic-heart-failure-preserved-ejection-fraction-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-03-31T10:47:05","modified_gmt":"2026-03-31T10:47:05","slug":"algocv0012-2018-biopharma-chronic-heart-failure-preserved-ejection-fraction-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0012-2018-biopharma-chronic-heart-failure-preserved-ejection-fraction-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>Heart failure with preserved ejection fraction (<abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr>) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> accounts for nearly half of all <abbr title=\"chronic heart failure\">CHF<\/abbr> cases, there are no therapies with a proven benefit approved for this patient population. Physicians usually prescribe <abbr title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors or AIIRAs, beta blockers, and diuretics with the focus to relieve symptoms and manage comorbidities such as hypertension, <abbr title=\"type 2 diabetes\">T2D<\/abbr>, or <abbr title=\"coronary artery disease\">CAD<\/abbr>. Unlike <abbr title=\"heart failure with reduced ejection fraction\">HFrEF<\/abbr>, calcium-channel blockers can be used in this patient population. The <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> Treatment Algorithm provides insight into prescribing patterns of a <abbr title=\"chronic heart failure\">CHF<\/abbr> subpopulation that offers huge commercial opportunity to a drug that\u00a0is evaluated specifically in this population.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients?<\/li>\n<li>How frequently is each drug class prescribed in the treatment of <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients?<\/li>\n<li>What proportion of <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated <abbr title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> patients?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390447","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390447\/revisions"}],"predecessor-version":[{"id":393572,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390447\/revisions\/393572"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}